Disc Medicine (IRON) Net Income towards Common Stockholders (2020 - 2026)
Disc Medicine (IRON) reported Net Income towards Common Stockholders of -$63.5 million for Q1 2026, down 86.81% year-over-year from -$481.2 million in Q1 2025, and down 4.26% quarter-over-quarter from -$60.9 million in Q4 2025.
Disc Medicine (IRON) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$63.5 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$63.5 million, down 86.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$241.9 million (down 107.85% YoY), and the FY2025 annual result was -$212.5 million, down 94.33% from the prior year.
- Net Income towards Common Stockholders slipped to -$63.5 million in Q1 2026 per IRON's latest filing, from -$60.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$9.6 million in Q2 2022 and troughed at -$63.5 million in Q1 2026.
- A 5-year average of -$29.9 million and a median of -$26.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 48.27% in 2022 and fell as far as 161.83% in 2022.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$11.2 million in 2022, then tumbled by 109.7% to -$23.6 million in 2023, then slipped by 24.93% to -$29.5 million in 2024, then slumped by 106.61% to -$60.9 million in 2025, then fell by 4.26% to -$63.5 million in 2026.
- Business Quant data shows IRON's Net Income towards Common Stockholders at -$63.5 million in Q1 2026, -$60.9 million in Q4 2025, and -$62.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Disc Medicine | 2.62 Bn | 1.89 Bn | - | -63.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.45 Mn |
| Dec 31, 2025 | -60.86 Mn |
| Sep 30, 2025 | -62.32 Mn |
| Jun 30, 2025 | -55.25 Mn |
| Mar 31, 2025 | -33.97 Mn |
| Dec 31, 2024 | -29.46 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -26.35 Mn |
| Mar 31, 2024 | -26.95 Mn |
| Dec 31, 2023 | -23.58 Mn |
| Sep 30, 2023 | -14.12 Mn |
| Jun 30, 2023 | -15.95 Mn |
| Mar 31, 2023 | -22.78 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Sep 30, 2022 | -16.15 Mn |
| Jun 30, 2022 | -9.58 Mn |
| Mar 31, 2022 | -9.85 Mn |
| Dec 31, 2021 | 18.19 Mn |
| Sep 30, 2021 | -18.45 Mn |
| Jun 30, 2021 | -16.45 Mn |